Researchers at Durham University, in collaboration with international partners, have developed a robotic system that allows ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with ...

There are problems within the health system that mean full patient access to training on how to use the insulin pumps will ...

Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...

Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items. Abbott maintains its full-year 2024 organic sales growth guidance range ...

Continuous glucose monitoring (CGM) technologies have transformed diabetes management by providing real-time, accurate ...

Pharmac's decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live ...